Clinical data confirm the high expression of EGFR compared to normal tissues, especially in glioblastoma multiforme, as well as head and neck cancers, which include tongue squamous cell carcinoma, and slightly lower in prostate cancer. The gene discussed is EGFR; the disease is prostate cancer.